MUSCLE RELAXANT AND ANALGESIC CAPLETS TABLET

Pays: Canada

Langue: anglais

Source: Health Canada

Ingrédients actifs:

IBUPROFEN; METHOCARBAMOL

Disponible depuis:

INTERNATIONAL PHARMACEUTICAL GENERICS LTD

Code ATC:

M03BA53

DCI (Dénomination commune internationale):

METHOCARBAMOL, COMBINATIONS EXCL PSYCHOLEPTICS

Dosage:

200MG; 500MG

forme pharmaceutique:

TABLET

Composition:

IBUPROFEN 200MG; METHOCARBAMOL 500MG

Mode d'administration:

ORAL

Unités en paquet:

100

Type d'ordonnance:

OTC

Domaine thérapeutique:

CENTRALLY ACTING SKELETAL MUSCLE RELAXANTS

Descriptif du produit:

Active ingredient group (AIG) number: 0248961001; AHFS:

Statut de autorisation:

CANCELLED PRE MARKET

Date de l'autorisation:

2017-06-13

Résumé des caractéristiques du produit

1 | P a g e
PRODUCT MONOGRAPH
MUSCLE RELAXANT & ANALGESIC CAPLETS
500 MG METHOCARBAMOL AND 200 MG IBUPROFEN TABLETS
THERAPEUTIC CLASSIFICATION
MUSCLE RELAXANT / ANALGESIC
INTERNATIONAL PHARMACEUTICAL GENERICS LTD.,
Date of Preparation:
30 Malta Avenue, Suite 2408
February 01, 2010
Brampton, ON
L6Y 4S5
Control#: 135919
2 | P a g e
TABLE
OF CONTENTS
Clinical
Pharmacology..............................................................................................................................3
Indications:................................................................................................................................................7
Contraindications
......................................................................................................................................8
Warnings:..................................................................................................................................................8
Precautions..............................................................................................................................................12
Drug Interactions
....................................................................................................................................13
Adverse Reactions
..................................................................................................................................15
Symptoms and Treatment of
Overdose...................................................................................................17
Dosage and
Administration.....................................................................................................................18
Pharmaceutical
Information....................................................................................................................19
Composition:...........................................................................................................................................21
Availability of Dosage
Forms............